PAVmed
420 Lexington Avenue
Suite 300
New York
New York
10170
United States
Tel: 212-401-1951
Website: http://www.pavm.com/
Email: info@pavmedinc.com
95 articles about PAVmed
-
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
3/26/2024
PAVmed Inc. provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. and Veris Health Inc., and presented financial results for the year ended December 31, 2023.
-
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
3/13/2024
PAVmed Inc. today announced that it will host a business update conference call and webcast on Wednesday, March 27, 2024, at 8:30 AM ET.
-
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
2/15/2024
Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced that its Chairman and Chief Executive Officer, Lishan Aklog, M.D., highlighted Lucid's EsoCheck® Cell Collection Device during testimony before the U.S. House of Representatives' Committee on Small Business.
-
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split - December 04, 2023
12/4/2023
PAVmed Inc. announced a dividend of approximately 3.3 million shares of common stock of its majority-owned subsidiary, Lucid Diagnostics Inc., which equals the number of shares PAVmed will receive in the contemporaneous partial settlement of outstanding intercompany debt owed to PAVmed by Lucid.
-
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection
10/31/2023
Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced two longitudinal clinical registries which are collecting real-world clinical utility and clinical validity data on EsoGuard® Esophageal DNA testing for the detection of esophageal precancer.
-
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference
9/21/2023
PAVmed Inc. and its majority-owned subsidiary Lucid Diagnostics Inc. announced their participation in the 2023 Cantor Fitzgerald Global Healthcare Conference in New York City.
-
PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
6/28/2023
PAVmed Inc. announced that it received a written notice from the Nasdaq Stock Market LLC granting the Company a 180-day extension to regain compliance with Nasdaq's $1.00 minimum bid price requirement as set forth in Nasdaq Listing Rule 5550.
-
PAVmed Provides Business Update and First Quarter Financial Results
5/16/2023
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company") today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended March 31, 2023.
-
PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023
5/5/2023
PAVmed Inc., a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, announced that it will host a business update conference call and webcast on Wednesday, May 17, 2023, at 8:30 AM EST.
-
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023
5/5/2023
Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc., announced that it will host a business update conference call and webcast on Tuesday, May 16, 2023, at 8:30 AM EST.
-
Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference
4/18/2023
Lucid Diagnostics Inc. announced that Dr. Lishan Aklog, Chairman and Chief Executive Officer; and Dennis McGrath, Chief Financial Officer will present at the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 11:00 AM ET.
-
Lucid Diagnostics Reports Publication of Future Effective Foundational Local Coverage Determination by Medicare Administrative Contractor Noridian Healthcare Solutions
4/18/2023
Lucid Diagnostics Inc. announced that Noridian Healthcare Solutions, the Medicare Administrative Contractor whose geographic Jurisdiction E covers Lucid's CLIA laboratory in Lake Forest, CA, has published a Future Effective Local Coverage Determination DL39262, on molecular testing for esophageal precancer and cancer in Medicare beneficiaries, to become effective May 28, 2023.
-
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results
3/14/2023
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company") today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the year ended December 31, 2022.
-
PAVmed to Hold a Business Update Conference Call and Webcast on March 15, 2023
3/3/2023
PAVmed Inc., a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, announced that it will host a business update conference call and webcast on Wednesday, March 15, 2023, at 8:30 AM EST.
-
PAVmed Digital Health Subsidiary Veris Health's Veris Cancer Care Platform™ Goes Live
2/28/2023
PAVmed Inc. announced that the Veris Cancer Care Platform™, designed to enhance personalized cancer care through remote patient monitoring, is now live following successful onboarding of the first cohort of cancer patients and their clinicians.
-
PAVmed and Lucid Diagnostics Provide Strategic Business Update
1/17/2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”) and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or “Lucid Diagnostics”) today provided a strategic business update, outlining near-term strategic priorities and resource reallocation.
-
PAVmed and Lucid Diagnostics to Provide Strategic Business Update
1/11/2023
PAVmed Inc. and its majority-owned subsidiaries Lucid Diagnostics Inc. and Veris Health Inc. today announced they will hold a joint conference call to provide a strategic business update on Tuesday, January 17, 2023 at 4:30PM EDT.
-
PAVmed Partners with Novosound on Ultrasound Imaging Technology
12/22/2022
PAVmed Inc. today announced that it has entered into a license option and joint research and development agreement with Novosound Ltd.
-
Ultrasound Sensor Specialist Novosound Inks Deal With Nasdaq-listed PAVmed Inc. to Advance Intravascular Imaging Technology
12/21/2022
Ultrasound sensor specialist Novosound has signed a commercial partnership agreement with PAVmed Inc., the Nasdaq-listed diversified medical technology company, to develop technology aimed at advancing intravascular imaging.
-
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
12/15/2022
PAVmed Inc., a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, announced that its majority-owned digital health subsidiary Veris Health Inc., has commercially launched its Veris Cancer Care Platform™.